Answers are grounded in this paper and cite their sources.
Tofacitinib is an oral small-molecule Janus kinase (JAK) inhibitor used to treat moderate or severe rheumatoid arthritis. The agent provides a new therapeutic approach against rheumatoid arthritis and was approved in Japan in 2013. Reports indicate positive effects also for the treatment of psoriatic arthritis and alopecia areata. Tofacitinib can lower the ability of the immune system to fight infections such as herpes zoster and opportunistic infections and increases cancer risks. However, we are not aware of any report of palmoplantar pustulosis–like eruptions caused by tofacitinib therapy.
No takes yet. Share an insight, caveat, or question.
Shibata et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: